-
Three phase III clinical trials of two oral agents for the treatment of multiple sclerosis were found to have a beneficial effect on clinical and MRI markers of disease activity, but there is a heightened concern for long-term safety due to cases of malignancy reported in each of the three studies.
-
Colocalized PET-CT is the most sensitive and accurate method for identifying an underlying neoplasm in paraneoplastic neurological syndromes.
-
Pramipexole has more than a simple additive benefit in augmenting the motor benefits of levodopa, but also increases the duration and severity of dyskinesias.
-
The authors hypothesize that postictal autonomic dysregulation, as measured by decreased heart rate variability, is a key factor in sudden death in epileptics.
-
In this prospective, population-based study of 13,549 middle-age black and white men and women in four U.S. communities, who, at the time of enrollment were free of cancer and cardiovascular disease, the investigators showed that abdominal obesity raised the risk of stroke in all groups, men and women, white and black.
-
-
Two oral medications for relapsing-remitting MS in phase III development; antihypertensives find new uses; Ginkgo biloba does not prevent cognitive decline in elderly; and FDA Actions.
-
Valproic acid and phenytoin were equally effective in the treatment of acute repetitive seizures and status epilepticus.
-
There are no randomized controlled treatment trials of cervical artery dissection, and the most effective therapy is uncertain.
-
5-α reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
